People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Syncardia: Maker of the Total Artificial Heart names Michael Garippa president July 2. Garippa was former CEO of CardiacAssist, developer of the TandemHeart ventricular assist system. Rodger Ford will continue on as Syncardia's CEO. The firm decided to make the change after the start of an FDA pre-market trial of its Freedom portable driver and after receiving CE approval to market the device in Europe. According to Syncardia, Garippa took CardiacAssist from an R&D firm that had lost an aggregate $50 million to a successful firm with over $6 million in net income in the past 24 months. He is replaced at CardiacAssist by Kraig McEwen
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.